EveryONE Medicines Names Kent Rogers Chief Executive Officer and Josh Ofman, MD, PhD, as Chairman of the Board

Kent Rogers, CEO of EveryONE Medicines (Photo: Business Wire)

Josh Ofman, CEO of EveryONE Medicines (Photo: Business Wire)

BOSTON, July 10, 2024–(BUSINESS WIRE)–EveryONE Medicines, the first biotechnology company dedicated exclusively to developing personalized genetic medicines, announced the appointment of Kent Rogers as Chief Executive Officer and Josh Ofman, MD, PhD, as Chairman of the Board.

Founded with seed funding from Khosla Ventures, GV, Third Rock Ventures and a private healthcare investment fund to develop a scalable treatment pathway tailored to individual patients with unique genetic mutations, EveryONE Medicines is initially focused on antisense oligonucleotides (ASOs) for rare neurological diseases and plans to expand to additional treatments for multiple disease types over time.

ASOs are currently used for a number of rare diseases, where “rare” by definition means 1 in 200,000 people in the US and 1 in 2,000 people in Europe. The need to develop treatments for rare diseases is underscored by the fact that more than 90% of rare diseases have no targeted treatment and 70-80% of rare diseases are caused by changes in single genes for which ASO therapies could provide disease-modifying benefits.

Inspired by Mila’s story, EveryONE Medicines was founded to make personalized medicine commercially viable and accessible to anyone who could benefit. Mila was diagnosed with a rare, fatal neurodegenerative disease. In a race against time, Dr. Timothy Yu of Boston Children’s Hospital developed Milasen, an ASO tailored to Mila’s unique mutation, making her the first person in the world to receive a personalized treatment designed just for one person. Inspired by this success, Mila’s mother, Julia Vitarello, co-founded EveryONE Medicines to make this approach a common treatment for patients with rare diseases.

“Our business model is unique in the industry, leveraging cutting-edge genomic sequencing, AI-driven innovation, and advanced manufacturing capabilities, as well as growing regulatory support, to provide answers to neurological diseases that affect the few or the few versus the many,” said Kent Rogers, CEO of EveryONE Medicines. “By rethinking traditional drug development, we are addressing a critical unmet need for patients with rare genetic disorders, offering hope where previously there was no viable path to developing new therapies in a timely manner. We are committed to creating a future where personalized medicines become routine.”

“We are excited to welcome Kent as CEO of EveryONE Medicines,” said Dr. Nessan Bermingham, Partner at Khosla Ventures. “With over 30 years of experience in product commercialization, supply chain logistics, and go-to-market strategy, Kent brings a wealth of knowledge and experience to the team. His proven track record in life sciences and innovative approach to solving patient access challenges will be invaluable as we work to bring personalized genetic therapies to patients with rare diseases.”

Regulatory authorities in the US, UK and Europe have shown initial support for a new pathway to accelerate the development of personalized therapies that will help save patients’ lives. EveryONE Medicines has already secured preliminary agreements with European agencies for a shortened non-clinical development pathway that will significantly reduce development costs and timelines. Similar discussions are underway with the FDA to implement comparable pathways in the United States.

“Technology is no longer the limiting factor. We can now find the underlying genetic cause of a disease in children like Mila and develop a drug that addresses it, even if it affects just one or a few patients,” said Julia Vitarello. “It’s no longer a question of whether we can do it, but whether we will, and when? As patients with rare and common diseases are increasingly categorized into smaller groups, there is a desire for significant regulatory oversight and reimbursement change, enabling an entirely new business model for multiple, highly targeted drugs, each for a few or a few patients.”

“The current drug development process leaves too many patients with extremely rare diseases waiting too long for life-changing therapies,” said Josh Ofman, MD, MSHS, and president of EveryONE Medicines. “Our mission is to pave a faster, more cost-effective path to new medicines that can be delivered on time. No patient should be left behind.”

About EveryONE Medicines

EveryONE Medicines is the first company in the world to develop personalized genetic medicines. EveryONE Medicines is dedicated to developing medicines for extremely rare CNS disorders quickly and efficiently. With a foundation of commercial success and growing regulatory support, including a central role in the UK Rare Therapies Launch Pad, the company’s mission is to develop a new, sustainable and scalable path for personalized genetic medicines. For more information, visit

View source version on


Kimberly Ha
KKH Advisors
[email protected]